$CRKN
Crown Electrokinetics Corp. Stock $crkn

$crkn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024028775 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$682.0K	$94.00K	$153.0K
YoY Change	3000.0%
Cost Of Revenue	$1.636M	$832.0K	$886.0K
YoY Change	5177.42%
Gross Profit	-$954.0K	-$738.0K	-$733.0K
YoY Change	10500.0%
Gross Profit Margin	-139.88%	-785.11%	-479.08%
Selling, General & Admin	$1.783M	$4.036M	$14.96M
YoY Change	-50.14%	70.51%	36.01%
% of Gross Profit
Research & Development	$756.0K	$708.0K	$2.231M
YoY Change	39.74%	21.23%	-45.68%
% of Gross Profit
Depreciation & Amortization	$212.0K	$193.0K	$733.0K
YoY Change	-99.83%	34.97%	1493.48%
% of Gross Profit
Operating Expenses	$2.539M	$5.477M	$17.93M
YoY Change	-38.33%	85.6%	18.65%
Operating Profit	-$3.705M	-$6.215M	-$18.66M
YoY Change	-10.2%		23.5%
Interest Expense	$860.0K	-$2.447M	-$16.06M
YoY Change	-57.36%	1531.33%	-229471.43%
% of Operating Profit
Other Income/Expense, Net	-$907.0K	$5.000K	$8.725M
YoY Change	-149.67%	-99.47%	1000.25%
Pretax Income	-$4.612M	-$9.306M	-$28.98M
YoY Change	100.52%	332.43%	102.47%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$4.612M	-$9.506M	-$29.66M
YoY Change	100.52%	335.26%	107.2%
Net Earnings / Revenue	-676.25%	-10112.77%	-19385.62%
Basic Earnings Per Share	-$0.13		-$5.46
Diluted Earnings Per Share	-$0.13	-$0.56	-$5.46
COMMON SHARES
Basic Shares Outstanding	51.70M shares	12.64M shares	5.429M shares
Diluted Shares Outstanding	36.68M shares		5.429M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$290.0K	$1.059M	$1.059M
YoY Change	-86.44%	28.99%	28.99%
Cash & Equivalents	$300.0K	$1.059M
Short-Term Investments
Other Short-Term Assets	$351.0K	$728.0K	$728.0K
YoY Change	261.86%	1055.56%	23.39%
Inventory
Prepaid Expenses
Receivables	$776.0K	$83.00K	$83.00K
Other Receivables	$576.0K	$0.00	$0.00
Total Short-Term Assets	$2.455M	$1.870M	$1.870M
YoY Change	-14.19%	32.53%	32.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.036M	$4.830M	$4.830M
YoY Change	20.09%	242.8%	48.57%
Goodwill		$652.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$165.0K	$1.445M	$1.445M
YoY Change	-22.54%	702.78%	337.88%
Total Long-Term Assets	$6.422M	$7.657M	$7.657M
YoY Change	-57.49%	47.85%	47.85%
TOTAL ASSETS
Total Short-Term Assets	$2.455M	$1.870M	$1.870M
Total Long-Term Assets	$6.422M	$7.657M	$7.657M
Total Assets	$8.877M	$9.527M	$9.527M
YoY Change	-50.6%	44.57%	44.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.297M	$1.500M	$1.500M
YoY Change	100.44%	73.41%	73.41%
Accrued Expenses	$962.0K	$1.767M	$1.767M
YoY Change	318.26%	184.54%	47.87%
Deferred Revenue	$1.260M	$2.000K
YoY Change
Short-Term Debt	$93.00K	$429.0K	$429.0K
YoY Change	-98.03%	-74.19%	-74.19%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.261M	$3.776M	$3.776M
YoY Change	-41.65%	-19.56%	-19.56%
LONG-TERM LIABILITIES
Long-Term Debt	$328.0K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$970.0K	$1.074M	$1.074M
YoY Change	-19.7%	-21.38%	-21.38%
Total Long-Term Liabilities	$1.298M	$1.074M	$1.074M
YoY Change	7.45%	-21.38%	-21.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.261M	$3.776M	$3.776M
Total Long-Term Liabilities	$1.298M	$1.074M	$1.074M
Total Liabilities	$6.559M	$4.850M	$4.850M
YoY Change	-35.85%	-19.97%	-19.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$121.6M	-$117.0M
YoY Change	34.65%	32.95%
Common Stock	$10.00K	$7.000K
YoY Change	150.0%	250.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.318M	$4.677M	$4.677M
YoY Change
Total Liabilities & Shareholders Equity	$8.877M	$9.527M	$9.527M
YoY Change	-50.6%	44.57%	44.57%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.612M	-$9.506M	-$29.66M
YoY Change	100.52%	335.26%	107.2%
Depreciation, Depletion And Amortization	$212.0K	$193.0K	$733.0K
YoY Change	-99.83%	34.97%	1493.48%
Cash From Operating Activities	-$2.700M	-$4.350M	-$16.16M
YoY Change	-42.89%	40.73%	45.06%
INVESTING ACTIVITIES
Capital Expenditures	$63.00K	$1.093M	$2.173M
YoY Change	-85.52%	131.08%	167.61%
Acquisitions			$645.0K
YoY Change
Other Investing Activities	$0.00	$5.000K	-$645.0K
YoY Change	-100.0%
Cash From Investing Activities	-$63.00K	-$1.088M	-$2.818M
YoY Change	-94.17%	130.02%	247.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$18.03M
YoY Change			2008.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.971M	4.444M	19.21M
YoY Change	-72.34%	9.92%	189.24%
NET CHANGE
Cash From Operating Activities	-$2.700M	-4.350M	-16.16M
Cash From Investing Activities	-$63.00K	-1.088M	-2.818M
Cash From Financing Activities	$1.971M	4.444M	19.21M
Net Change In Cash	-$769.0K	-994.0K	236.0K
YoY Change	-158.39%	-307.52%	-104.45%
FREE CASH FLOW
Cash From Operating Activities	-$2.700M	-$4.350M	-$16.16M
Capital Expenditures	$63.00K	$1.093M	$2.173M
Free Cash Flow	-$2.763M	-$5.443M	-$18.33M
YoY Change	-46.48%	52.72%	53.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	333-249833
CY2023	dei	Entity Registrant Name EntityRegistrantName	Crown Electrokinetics Corp.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5423944
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1110 NE Circle Blvd
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Corvallis
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	OR
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	97330
CY2023	dei	City Area Code CityAreaCode	(213)
CY2023	dei	Local Phone Number LocalPhoneNumber	600-4250
CY2023	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.0001 Per Share
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	8400000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51702036	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Costa Mesa, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1059000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	821000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	728000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	83000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1870000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1411000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3129000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1409000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1382000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1598000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1701000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1842000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	1306000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	150000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	139000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	180000	usd
CY2023Q4	us-gaap	Assets Assets	9527000	usd
CY2022Q4	us-gaap	Assets Assets	6590000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1500000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	865000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1190000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	621000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	655000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	574000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	972000	usd
CY2022Q4	crkn	Notes Payable At Fair Value NotesPayableAtFairValue	1654000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	429000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	8000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3776000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4694000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1072000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1366000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4850000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6060000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25744158	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	338033	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121665000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	516000	usd
CY2023	crkn	Stock Issuance Of Common Stockequity Line Of Credit Net Of Offering Costs StockIssuanceOfCommonStockequityLineOfCreditNetOfOfferingCosts	4489000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8228000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88533000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116995000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88005000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4677000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9527000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6590000	usd
CY2023	us-gaap	Revenues Revenues	153000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	886000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	733000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	503000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2231000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4107000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14962000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10498000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	649000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-19308000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15108000	usd
CY2023	us-gaap	Interest Expense InterestExpense	9417000	usd
CY2022	us-gaap	Interest Expense InterestExpense	7000	usd
CY2023	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	504000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2345000	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	64000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10458000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1023000	usd
CY2023	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-7040000	usd
CY2022	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-149000	usd
CY2023	crkn	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	401000	usd
CY2023	us-gaap	Other Expenses OtherExpenses	1293000	usd
CY2022	us-gaap	Other Expenses OtherExpenses	74000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9676000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	793000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28984000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14315000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28984000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14315000	usd
CY2023	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	6000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29660000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14370000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-54.12
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5429259	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	265502	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8988000	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	855000	usd
CY2022	crkn	Stock Issuance Of Common Stock Warrants In Connection With Sloc StockIssuanceOfCommonStockWarrantsInConnectionWithSLOC	223000	usd
CY2022	crkn	Stock Issued During The Period Preferred Stock And Warrants Net Of Fees Value StockIssuedDuringThePeriodPreferredStockAndWarrantsNetOfFeesValue	1039000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1249000	usd
CY2022	crkn	Stock Issued During Period Value Of Common Stock Warrants In Connection With Consideration Payable StockIssuedDuringPeriodValueOfCommonStockWarrantsInConnectionWithConsiderationPayable	86000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2405000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14315000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2062000	usd
CY2023	crkn	Stcok Issued During Period Valu Issuance Of Series E Preferred Stock In Connection With Loc StcokIssuedDuringPeriodValuIssuanceOfSeriesEPreferredStockInConnectionWithLOC	4350000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	298000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2023	crkn	Issuance Of Common Stock In Connection With Conversion Of2022 Notes IssuanceOfCommonStockInConnectionWithConversionOf2022Notes	2166000	usd
CY2023	crkn	Stock Issued During Period Value Series D Preferred Stock Exchanged For Series F Preferred Stock In Connection With Exchange Ag StockIssuedDuringPeriodValueSeriesDPreferredStockExchangedForSeriesFPreferredStockInConnectionWithExchangeAg	450000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1276000	usd
CY2023	crkn	Conversion Of Senior Secured Notes Into Series F Preferred Stock In Connection With Exchange ConversionOfSeniorSecuredNotesIntoSeriesFPreferredStockInConnectionWithExchange	82000	usd
CY2023	crkn	Stock Issued During Period Value Issuance Of Series F1 Preferred Stock StockIssuedDuringPeriodValueIssuanceOfSeriesF1PreferredStock	1372000	usd
CY2023	crkn	Stock Issued During Period Value Issuance Of Series F2 Preferred Stock StockIssuedDuringPeriodValueIssuanceOfSeriesF2PreferredStock	464000	usd
CY2023	crkn	Commitment To Issue Shares Of Common Stock In Connection With Senior Secured Notes CommitmentToIssueSharesOfCommonStockInConnectionWithSeniorSecuredNotes	2410000	usd
CY2023	crkn	Stock Issued During Period Value Credit Notes Common Stock Commitment Share Issuance StockIssuedDuringPeriodValueCreditNotesCommonStockCommitmentShareIssuance	230000	usd
CY2023	crkn	Stock Issued Durign Period Commitment To Issue Shares Of Series E Preferred Stock In Connection With Line Of Credit Notes StockIssuedDurignPeriodCommitmentToIssueSharesOfSeriesEPreferredStockInConnectionWithLineOfCreditNotes	3363000	usd
CY2023	crkn	Stock Issued Durign Period Commitment To Issue Shares Of Common Stock In Connection With Demand Notes StockIssuedDurignPeriodCommitmentToIssueSharesOfCommonStockInConnectionWithDemandNotes	286000	usd
CY2023	crkn	Stock Issued During Period Value Of Common Stock In Connection With Senior Secured Notes Settlement StockIssuedDuringPeriodValueOfCommonStockInConnectionWithSeniorSecuredNotesSettlement	1160000	usd
CY2023	crkn	Issuance Of Common Stock In Connections With Equity Line Of Credit IssuanceOfCommonStockInConnectionsWithEquityLineOfCredit	114000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	714000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28984000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4677000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28984000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14315000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	714000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2405000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	733000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	503000	usd
CY2023	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	504000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10458000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1023000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	401000	usd
CY2023	crkn	Gain On Issuance Of Convertible Note GainOnIssuanceOfConvertibleNote	64000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2345000	usd
CY2023	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes	-7040000	usd
CY2022	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes	-149000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9341000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	73000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	626000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	494000	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	628000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	649000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	200000	usd
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-214000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-144000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-61000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-182000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	83000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1253000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	413000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	440000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	323000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1062000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-396000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16160000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11140000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	645000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2173000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	751000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	61000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2818000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-812000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2062000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	855000	usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	8398000	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1295000	usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2350000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	170000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	46000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3500000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1039000	usd
CY2023	crkn	Proceeds From Issuance Of Series F1 Preferred Stock Net Of Fees ProceedsFromIssuanceOfSeriesF1PreferredStockNetOfFees	2328000	usd
CY2023	crkn	Proceeds From Issuance Of Series F2 Preferred Stock ProceedsFromIssuanceOfSeriesF2PreferredStock	748000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1357000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2348000	usd
CY2023	crkn	Proceeds From The Issuance Of Common Stock In Connection With Equity Line Of Credit Net Of Offeri ProceedsFromTheIssuanceOfCommonStockInConnectionWithEquityLineOfCreditNetOfOfferi	4489000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19214000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6643000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	238000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5309000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	821000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6130000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1059000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	821000	usd
CY2023	crkn	Issuance Of Series E Preferred Stock In Connection With Line Of Credit IssuanceOfSeriesEPreferredStockInConnectionWithLineOfCredit	4350000	usd
CY2023	crkn	Issuance Of Common Stock In Connection With Equity Line Of Credits IssuanceOfCommonStockInConnectionWithEquityLineOfCredits	114000	usd
CY2023	crkn	Issuance Of Series F Preferred Stock In Connection With Exchange Of Series D Preferred Stock IssuanceOfSeriesFPreferredStockInConnectionWithExchangeOfSeriesDPreferredStock	450000	usd
CY2023	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes IssuanceOfCommonStockInConnectionWithConversionOfNotes	2165000	usd
CY2023	crkn	Issuance Of Common Stock In Connection With Senior Secured Notes Settlement IssuanceOfCommonStockInConnectionWithSeniorSecuredNotesSettlement	1160000	usd
CY2022	crkn	Issuance Of Common Stock Warrants In Connection With Sloc IssuanceOfCommonStockWarrantsInConnectionWithSLOC	223000	usd
CY2023	crkn	Commitment To Issue Shares Of Common Stock In Connection With Demand Notes CommitmentToIssueSharesOfCommonStockInConnectionWithDemandNotes	286000	usd
CY2023	crkn	Conversion Of Senior Secured Notes Into Series F Preferred Stock In Connection With Exchange ConversionOfSeniorSecuredNotesIntoSeriesFPreferredStockInConnectionWithExchange	82000	usd
CY2022	crkn	Issuance Of Common Stock Warrants In Connection With Consideration Payable IssuanceOfCommonStockWarrantsInConnectionWithConsiderationPayable	86000	usd
CY2023	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	452000	usd
CY2022	crkn	Unpaid Equipment Included In Accounts Payable UnpaidEquipmentIncludedInAccountsPayable	94000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1168000	usd
CY2023	crkn	Reduction Of Right Of Use Asset And Operating Lease Liability Due To Early Lease Termination ReductionOfRightOfUseAssetAndOperatingLeaseLiabilityDueToEarlyLeaseTermination	853000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	14000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	7000	usd
CY2023Q3	crkn	Common Stock Conversion Shares CommonStockConversionShares	60	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1	shares
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 – Liquidity, Financial Condition, and Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As reflected in the consolidated financial statements, the Company had an accumulated deficit of approximately $117.0 million and negative working capital of approximately $1.9 million at December 31, 2023, a net loss of approximately $29.0 million, approximately $16.2 million of net cash used in operating activities, and $2.8 million of net cash used in investing activities for the year ended December 31, 2023. The Company expects to continue to incur ongoing administrative and other expenses, including public company expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has obtained additional capital through the sale of debt or equity financings or other arrangements to fund operations including through its existing at-the-market offering, $10.0 million Standing Letter of Credit (“SLOC”), $100.0 million line of credit, and $50.0 million equity line of credit; however, there can be no assurance that the Company will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing stockholders and newly issued shares may contain senior rights and preferences compared to currently outstanding shares of common stock. Issued debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued. Due to the uncertainty in the Company’s ability to raise capital, management believes that there is substantial doubt in the Company’s ability to continue as a going concern for twelve months from the issuance of these consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine, as well as Israel and Hamas. The Company’s financial condition and results of operations may be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine or any other geopolitical tensions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-117000000	usd
CY2023Q4	us-gaap	Cash Cash	1900000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16200000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2800000	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	100000000	usd
CY2023	crkn	Equity Line Of Credit EquityLineOfCredit	50000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but not limited to, valuation of its business combination, estimated fair value of convertible notes, estimated fair value of warrant lability, Series F/F-1/F-2 preferred stock, stock option awards for stock-based compensation and operating lease right-of-use assets and liabilities. In our MD&A, the Company discloses the impact of the estimated fair value of convertible notes and warrant liabilities on our consolidated results of operations, highlighting how changes in these valuations, driven by market conditions and our assumptions, significantly influence our financial performance. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk and Off-balance Sheet Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash is deposited in accounts at large financial institutions, and amounts may exceed the standard federally insured limits totaling $250,000. The Company has no financial instruments with off-balance sheet risk of loss as of December 31, 2023 and 2022.</p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	200000	usd
CY2022Q1	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.12	pure
CY2022Q1	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P2Y
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	200000	shares
CY2022Q1	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	50000	shares
CY2022Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1000000	usd
CY2022Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	5000000	usd
CY2023Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	100000	usd
CY2023	crkn	Percentage Of Payment Invoices PercentageOfPaymentInvoices	0.05	pure
CY2023	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	700000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-28984000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14315000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29660000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14370000	usd
CY2023	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	5431201	shares
CY2022	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	267440	shares
CY2023	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1942	shares
CY2022	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1938	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5429259	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	265502	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-54.12
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3826620	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	712497	shares
CY2023	crkn	Lease Liabilities LeaseLiabilities	1800000	usd
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	700000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Number Of Employees DefinedContributionPlanNumberOfEmployees	12	pure
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	200000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	655000	usd
CY2023Q4	crkn	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Security Deposits BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecurityDeposits	5000	usd
CY2023Q4	crkn	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses	529000	usd
CY2023Q4	crkn	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Notes Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable	338000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	-7000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	652000	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	645000	usd
CY2023Q4	crkn	Prepaid License Fees PrepaidLicenseFees	158000	usd
CY2022Q4	crkn	Prepaid License Fees PrepaidLicenseFees	300000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	26000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	142000	usd
CY2023Q4	crkn	Prepaid Professional Fees PrepaidProfessionalFees	53000	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	277000	usd
CY2023Q4	crkn	Prepaid Hudson Warrant PrepaidHudsonWarrant	86000	usd
CY2022Q4	crkn	Prepaid Hudson Warrant PrepaidHudsonWarrant	85000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	128000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	63000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	728000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2600000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2600000	usd
CY2023Q3	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	400000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2022-12-31
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4048000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1871000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	919000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	462000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3129000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1409000	usd
CY2023	us-gaap	Depreciation Depreciation	500000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	500000	usd
CY2022	us-gaap	Depreciation Depreciation	300000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	100000	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1800000	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1800000	usd
CY2023Q4	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2022Q4	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2023Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	4000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2179000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2175000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	797000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	577000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1382000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1598000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	235000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	234000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	197000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	194000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	195000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	327000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1382000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
CY2023Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Gross DebtIssuanceCostsLineOfCreditArrangementsGross	10647000	usd
CY2022Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Gross DebtIssuanceCostsLineOfCreditArrangementsGross	223000	usd
CY2023Q4	us-gaap	Accumulated Amortization Of Debt Issuance Costs Line Of Credit Arrangements AccumulatedAmortizationOfDebtIssuanceCostsLineOfCreditArrangements	9341000	usd
CY2022Q4	us-gaap	Accumulated Amortization Of Debt Issuance Costs Line Of Credit Arrangements AccumulatedAmortizationOfDebtIssuanceCostsLineOfCreditArrangements	73000	usd
CY2023Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	1306000	usd
CY2022Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	150000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	112000	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	104000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	51000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1000000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	510000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	27000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1190000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	621000	usd
CY2023Q2	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	600000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	crkn	Aggregate Amount AggregateAmount	50000000	usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.0499	pure
CY2023	crkn	Purchase Price Of Common Stock Percentage PurchasePriceOfCommonStockPercentage	0.97	pure
CY2023Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	3986991	shares
CY2023Q4	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	4500000	usd
CY2023	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	1.19
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.199	pure
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.05	pure
CY2020Q4	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	1000000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	178000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	508000	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	536000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1897000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	714000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2405000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	300000	usd
CY2023	crkn	Recognized Weightedaverage Term RecognizedWeightedaverageTerm	P0Y7M6D
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	225000	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	38000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P5Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	159295	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	158.4
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26188000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	225000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.23
CY2023	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y10M13D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1516	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	196.86
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	382779	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	65.04
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	156522	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	155.36
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M2D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	usd
CY2022Q4	crkn	Share Based Compensations Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationsArrangementByShareBasedPaymentAwardWarrantsOutstanding	461066	shares
CY2022Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingWeightedAverageExercisePrice	44.88
CY2022Q4	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Warrant Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M
CY2023	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssued	1405797	shares
CY2023Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Issued Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedWeightedAverageExercisePrice	11.42
CY2023Q4	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Issued Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedWeightedAverageRemainingContractualTerm	P4Y7M6D
CY2023	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercised	-106768	shares
CY2023Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisedWeightedAverageExercisePrice	19.2
CY2023Q4	crkn	Share Based Compensations Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationsArrangementByShareBasedPaymentAwardWarrantsOutstanding	1760095	shares
CY2023Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingWeightedAverageExercisePrice	18.96
CY2023Q4	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Warrant Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantOutstandingWeightedAverageRemainingContractualTerm2	P4Y4M24D
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	96894	shares
CY2022Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	100000	usd
CY2022Q3	crkn	Aggregate Purchase Shares AggregatePurchaseShares	5000	shares
CY2022Q3	us-gaap	Share Price SharePrice	45
CY2023Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	100000	usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3333	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	120
CY2022Q1	us-gaap	Equity Fair Value Disclosure EquityFairValueDisclosure	200000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	6400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14539000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8438000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	729000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	923000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	227000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	25000	usd
CY2023Q4	crkn	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	392000	usd
CY2022Q4	crkn	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	409000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	968000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	707000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	168000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	78000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17023000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10580000	usd
CY2023Q4	crkn	Deffered Tax Assets Depreciation DefferedTaxAssetsDepreciation	105000	usd
CY2022Q4	crkn	Deffered Tax Assets Depreciation DefferedTaxAssetsDepreciation	46000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	386000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	388000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16532000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10146000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	58900000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	44300000	usd
CY2023Q4	crkn	Net Operating Loss Carryforwards Federal NetOperatingLossCarryforwardsFederal	58800000	usd
CY2023	crkn	Taxable Income Percentage TaxableIncomePercentage	0.80	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.017	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001	pure
CY2023	crkn	Effective Income Tax Rate Reconciliation Permanent Items Percent EffectiveIncomeTaxRateReconciliationPermanentItemsPercent	0.009	pure
CY2022	crkn	Effective Income Tax Rate Reconciliation Permanent Items Percent EffectiveIncomeTaxRateReconciliationPermanentItemsPercent	0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.04	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.015	pure
CY2023	crkn	Effective Income Tax Rate Reconciliation Deferred Tax Trueup Return To Provision EffectiveIncomeTaxRateReconciliationDeferredTaxTrueupReturnToProvision	-0.003	pure
CY2022	crkn	Effective Income Tax Rate Reconciliation Deferred Tax Trueup Return To Provision EffectiveIncomeTaxRateReconciliationDeferredTaxTrueupReturnToProvision	0.046	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.22	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.138	pure
CY2016Q1	us-gaap	Area Of Land AreaOfLand	1700	sqft
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	41323	usd
CY2016Q1	crkn	Operating Lease Expires Date OperatingLeaseExpiresDate	2025-06-30
CY2021Q1	us-gaap	Area Of Land AreaOfLand	3500	sqft
CY2021Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P39M
CY2021Q1	crkn	Operating Lease Expires Date OperatingLeaseExpiresDate	2024-06-30
CY2021Q2	us-gaap	Area Of Land AreaOfLand	3694	sqm
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P60M
CY2021Q2	crkn	Operating Lease Expires Date OperatingLeaseExpiresDate	2027-01-31
CY2021Q4	us-gaap	Area Of Land AreaOfLand	26963	sqm
CY2021Q4	crkn	Operating Lease Expires Date OperatingLeaseExpiresDate	2027-02-28
CY2023Q4	crkn	Termination Fee TerminationFee	100000	usd
CY2023Q4	us-gaap	Lease Deposit Liability LeaseDepositLiability	200000	usd
CY2023Q2	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	100000	usd
CY2023Q2	us-gaap	Loss On Contract Termination LossOnContractTermination	100000	usd
CY2023Q2	us-gaap	Lease Deposit Liability LeaseDepositLiability	200000	usd
CY2023Q4	us-gaap	Area Of Land AreaOfLand	1225	sqft
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P36M
CY2023Q4	crkn	Operating Lease Expires Date OperatingLeaseExpiresDate	2026-10-31
CY2023Q4	us-gaap	Lease Deposit Liability LeaseDepositLiability	31450	usd
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P48M
CY2023Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	23060	usd
CY2023Q4	us-gaap	Lease Deposit Liability LeaseDepositLiability	23060	usd
CY2023Q4	crkn	Total Sale Price Percentage TotalSalePricePercentage	0.25	pure
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2023	us-gaap	Revenues Revenues	153000	usd
CY2023	us-gaap	Revenues Revenues	153000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	886000	usd
CY2023	us-gaap	Gross Profit GrossProfit	-733000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	733000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2231000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14962000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	649000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-19308000	usd
CY2023	us-gaap	Interest Expense InterestExpense	9417000	usd
CY2023	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	504000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2345000	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	64000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10458000	usd
CY2023	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-7040000	usd
CY2023	crkn	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	401000	usd
CY2023	us-gaap	Other Expenses OtherExpenses	1293000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9676000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28984000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	139000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	180000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2023Q4	crkn	Notes Payable At Fair Value NotesPayableAtFairValue		usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2022	crkn	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5429259	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	265502	shares
CY2023	crkn	Deemed Dividend For Repricing Of Series D Preferred Stock DeemedDividendForRepricingOfSeriesDPreferredStock		usd
CY2023	crkn	Issuance Of Common Stock In Connection With Series A And Series B Dividends IssuanceOfCommonStockInConnectionWithSeriesAAndSeriesBDividends		usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
CY2023	crkn	Conversion Of Series F Preferred Stock Into Common Stocks ConversionOfSeriesFPreferredStockIntoCommonStocks		usd
CY2023	crkn	Conversion Of Series F1 Preferred Stock Into Common Stock ConversionOfSeriesF1PreferredStockIntoCommonStock		usd
CY2023	crkn	Stock Issuance Of Common Stock To Settle Commitment Shares StockIssuanceOfCommonStockToSettleCommitmentShares		usd
CY2023	crkn	Stock Issued During Period Reverse Stock Split Rounding StockIssuedDuringPeriodReverseStockSplitRounding		usd
CY2022	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability		usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	crkn	Gain On Issuance Of Convertible Note GainOnIssuanceOfConvertibleNote		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	crkn	Proceeds From Issuance Of Series F1 Preferred Stock Net Of Fees ProceedsFromIssuanceOfSeriesF1PreferredStockNetOfFees		usd
CY2022	crkn	Proceeds From Issuance Of Series F2 Preferred Stock ProceedsFromIssuanceOfSeriesF2PreferredStock		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	crkn	Proceeds From The Issuance Of Common Stock In Connection With Equity Line Of Credit Net Of Offeri ProceedsFromTheIssuanceOfCommonStockInConnectionWithEquityLineOfCreditNetOfOfferi		usd
CY2022	crkn	Issuance Of Series E Preferred Stock In Connection With Line Of Credit IssuanceOfSeriesEPreferredStockInConnectionWithLineOfCredit		usd
CY2022	crkn	Issuance Of Common Stock In Connection With Equity Line Of Credits IssuanceOfCommonStockInConnectionWithEquityLineOfCredits		usd
CY2022	crkn	Issuance Of Series F Preferred Stock In Connection With Exchange Of Series D Preferred Stock IssuanceOfSeriesFPreferredStockInConnectionWithExchangeOfSeriesDPreferredStock		usd
CY2022	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes IssuanceOfCommonStockInConnectionWithConversionOfNotes		usd
CY2022	crkn	Issuance Of Common Stock In Connection With Senior Secured Notes Settlement IssuanceOfCommonStockInConnectionWithSeniorSecuredNotesSettlement		usd
CY2023	crkn	Issuance Of Common Stock Warrants In Connection With Sloc IssuanceOfCommonStockWarrantsInConnectionWithSLOC		usd
CY2022	crkn	Commitment To Issue Shares Of Common Stock In Connection With Demand Notes CommitmentToIssueSharesOfCommonStockInConnectionWithDemandNotes		usd
CY2022	crkn	Conversion Of Senior Secured Notes Into Series F Preferred Stock In Connection With Exchange ConversionOfSeniorSecuredNotesIntoSeriesFPreferredStockInConnectionWithExchange		usd
CY2023	crkn	Issuance Of Common Stock Warrants In Connection With Consideration Payable IssuanceOfCommonStockWarrantsInConnectionWithConsiderationPayable		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	crkn	Reduction Of Right Of Use Asset And Operating Lease Liability Due To Early Lease Termination ReductionOfRightOfUseAssetAndOperatingLeaseLiabilityDueToEarlyLeaseTermination		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-54.12
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.46
CY2022Q4	crkn	Prepaid Professional Fees PrepaidProfessionalFees		usd
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent		usd
CY2022Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross		usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent		usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent		usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2023	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingIntrinsicValue		usd
CY2023Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Issued In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardIssuedInPeriodGrantDateIntrinsicValue		usd
CY2023Q4	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
CY2023Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodTotalIntrinsicValue		usd
CY2023Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Revenues Revenues		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001761696
CY2023	dei	Trading Symbol TradingSymbol	CRKN

Files In Submission

Name	View Source	Status
0001213900-24-028775-index-headers.html	Edgar Link	pending
0001213900-24-028775-index.html	Edgar Link	pending
0001213900-24-028775.txt	Edgar Link	pending
0001213900-24-028775-xbrl.zip	Edgar Link	pending
crkn-20231231.xsd	Edgar Link	pending
ea0202229-10k_crown.htm	Edgar Link	pending
ea020222901ex21-1_crown.htm	Edgar Link	pending
ea020222901ex31-1_crown.htm	Edgar Link	pending
ea020222901ex31-2_crown.htm	Edgar Link	pending
ea020222901ex32-1_crown.htm	Edgar Link	pending
ea020222901ex32-2_crown.htm	Edgar Link	pending
ea020222901ex4-15_crown.htm	Edgar Link	pending
ea020222901ex97-1_crown.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
crkn-20231231_cal.xml	Edgar Link	unprocessable
crkn-20231231_def.xml	Edgar Link	unprocessable
crkn-20231231_lab.xml	Edgar Link	unprocessable
crkn-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0202229-10k_crown_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRKN
Crown Electrokinetics Corp. Stock $crkn

2024 Q1 Form 10-K Financial Statement

#000121390024028775 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN Crown Electrokinetics Corp. Stock $crkn

2024 Q1 Form 10-K Financial Statement

#000121390024028775 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN
Crown Electrokinetics Corp. Stock $crkn